Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Ozempic (semaglutide) can lower blood pressure, promote 5–15% weight loss, and reduce major adverse cardiovascular events by roughly 26% in high-risk adults—suggesting meaningful heart-protective benefits that may extend to Black adults, who face disproportionately high rates of hypertension, obesity, and cardiovascular disease.
However, fewer than 10% of clinical trial participants were Black, leaving open questions about side effects, optimal dosing, and access barriers within this population. Common side effects include nausea, vomiting, and gastrointestinal issues, while cost and insurance coverage remain significant hurdles.
If you're weighing whether Ozempic or another treatment fits your health goals, don't guess. Symptoms like elevated blood pressure, unexplained weight changes, or fatigue can point to several underlying conditions—each with different treatment paths. A free, instant, online symptom check can help you understand what's driving how you feel and guide your next conversation with a doctor. It takes just a few minutes, requires no sign-up, and gives you clearer footing before making decisions about medications like Ozempic.
Reviewed for medical accuracy: 07/21/2026
Maintaining a healthy heart is vital for everyone, especially for Black adults who face higher rates of hypertension, diabetes, and cardiovascular disease. Ozempic (semaglutide) is a medication originally approved for type 2 diabetes that has gained attention for its potential benefits on heart health. In this note, we'll break down what we know about Ozempic and heart health, focusing on how it may affect Black adults, any gaps in the data, and practical guidance on staying safe and informed.
While originally developed for diabetes, clinicians noticed that patients on Ozempic often lost weight and had fewer cardiovascular events. This observation led to dedicated trials evaluating its impact on heart health.
Cardiovascular outcome trials are studies designed to see if a diabetes drug helps or harms the heart. For semaglutide, the key trial is SUSTAIN‐6.
SUSTAIN‐6 Trial
Note: While results are encouraging, this study was relatively short (about two years) and included mostly non-Black participants.
Real-World Observations
Key takeaway: Ozempic appears to have heart-protective effects, but most evidence comes from trials with limited Black representation.
Underrepresentation in Trials
Similar Biology, Similar Benefits
Potential Cultural and Access Barriers
Disparities in Cardiovascular Risk
Action point: Discuss your individual risk factors and medication plans with your healthcare team, ensuring they consider your personal and cultural needs.
No medication is without potential downsides. For Ozempic, be aware of:
Gastrointestinal side effects
Pancreatitis (rare)
Gallbladder issues
Diabetic retinopathy complications
Injection site reactions
Remember: The absolute risk of serious side effects is low, but vigilance matters. If something feels off, don't hesitate to reach out to a healthcare provider.
Start Low, Go Slow
Monitor Blood Pressure Regularly
Keep Up with Lab Tests
Combine with Lifestyle Changes
Stay Connected with Your Care Team
You might worry about starting a new medication. Here's how to feel more secure:
If you're experiencing symptoms and want to understand what might be happening with your health, you can get personalized guidance through Ubie's Medically approved LLM Symptom Checker Chat Bot to help you decide your next steps.
Always reach out if you experience:
Even minor issues are worth discussing. Early intervention can prevent bigger problems.
Ozempic offers promising benefits for heart health, especially by improving weight, blood pressure, and blood sugar control. While data specific to Black adults are limited, the underlying mechanisms suggest comparable advantages.
To make the best choice for your heart health:
Your heart health matters. Speak to a doctor about any serious or life-threatening concerns and to tailor a treatment plan that fits your needs.
(References)
* Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity without Diabetes Mellitus. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307592. Epub 2023 Nov 11. PMID: 37948797.
* Maras JS, et al. Racial/Ethnic Differences in the Effectiveness of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2024 Jan 18;109(2):e578-e587. doi: 10.1210/clinem/dgad672. PMID: 37905188.
* Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 16. PMID: 27637153.
* Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Oct 5;389(14):1257-1269. doi: 10.1056/NEJMoa2306994. Epub 2023 Aug 25. PMID: 37622692.
* Kristensen SL, et al. Cardiovascular and kidney outcomes of GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials. Lancet Diabetes Endocrinol. 2023 Aug;11(8):546-557. doi: 10.1016/S2213-8587(23)00155-2. Epub 2023 Jul 6. PMID: 37423377.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.